Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PRKCG | P05129 | 1/20 | 0.48 |
| ▸ | PRKCB | P05771 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PRKACG | P22612 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30098481 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL4783267 | 0.98 | LMNA (0.56) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL11270913 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL4785840 | 0.85 | TNF (0.49) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL31742311 | 0.85 | TNF (0.49) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL2627867 | 0.81 | LMNA (0.53) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL843758 | 0.81 | LMNA (0.53) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL6597218 | 0.81 | CYP3A4 (0.53) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL31177930 | 0.81 | KDM4E (0.58) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL3816382 | 0.81 | CYP3A4 (0.53) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| EP-3738958-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | ChemoCentryx, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020132045-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEUROPROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2016201052-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-1506166-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-25 | — | — | US | disclosed |
| WO-2003097586-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
| US-6534510-B2 | Anticoagulants | MERCK & CO., INC. | 2003-03-18 | — | — | US | disclosed |
| EP-1267876-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006923-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001070229-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1074545-A1 | ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Hidaka, Hiroyoshi (JP) | 2001-02-07 | — | — | EP | disclosed |
| US-4337256-A | ANTIINFLAMMATORY AGENTS; ANTIAGGLOMERANTS; ENZYME INHIBITORS; ANTIULCER AGENTS | TEIKOKU HORMONE MANUFACTURING CO., LTD. (JP) | 1982-06-29 | — | — | US | disclosed |
| EP-0013411-A1 | Isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1980-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | CYP3A4 4302/4885CYP2D6 4276/4885LMNA 1261/4885 |
| US-20020006923-A1 | Thrombin inhibitors | F2, F11, F12 | CYP3A4 1332/4885CYP2D6 1128/4885LMNA 1877/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | CYP3A4 4393/4885CYP2D6 2976/4885LMNA 4183/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | CYP3A4 4851/4885CYP2D6 4825/4885LMNA 1527/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | CYP3A4 4393/4885CYP2D6 2976/4885LMNA 4183/4885 |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | UTS2R, TRPV6, TRPV1 | CYP3A4 1466/4885CYP2D6 1020/4885LMNA 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.